ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Cancer

Expert Panel on Urological Imaging

Research output: Contribution to journalArticlepeer-review

8 Scopus citations

Abstract

Renal cell carcinoma (RCC) accounts for most malignant renal tumors and is considered the most lethal of all urologic cancers. For follow-up of patients with treated or untreated RCC and those with neoplasms suspected to represent RCC, radiologic imaging is the most useful component of surveillance, as most relapses and cases of disease progression are identified when patients are asymptomatic. Understanding the strengths and limitations of the various imaging modalities for the detection of disease, recurrence, or progression is important when planning follow-up regimens. This publication addresses the appropriate imaging examinations for asymptomatic patients who have been treated for RCC with radical or partial nephrectomy, or ablative therapies. It also discusses the appropriate imaging examinations for asymptomatic patients with localized biopsy-proven or suspected RCC undergoing active surveillance. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

Original languageEnglish (US)
Pages (from-to)S399-S416
JournalJournal of the American College of Radiology
Volume16
Issue number11
DOIs
StatePublished - Nov 1 2019

Funding

Dr Kishan reported receiving personal fees from ViewRay, Inc, Varian Medical Systems, Inc, Intelligent Automation, Inc., and Janssen Pharmaceuticals outside the submitted work. Dr Lockhart discloses receiving salary as Deputy Editor of Journal of Ultrasound in Medicine; Royalties, Elsevier Publishers; Royalties, Oxford Publishers. Dr Lyshchik reports personal fees and research support from General Electric, grants and non-financial support from Bracco Diagnostics, book royalties from Elsevier, Board of Governors and Deputy Editor of JUM from AIUM, outside the submitted work. Dr Purysko reports core radiology services from Profound medical, outside the submitted work. Dr Smith reports grants from General Electric, other from eMASS LLC, other from Radiostics LLC, outside the submitted work; In addition, Dr Smith has a patent Artificial intelligence-assisted tumor response with royalties paid, and a patent Target lesion tracking issued. The other authors state that they have no conflict of interest related to the material discussed in this article. Dr Kishan reported receiving personal fees from ViewRay, Inc, Varian Medical Systems, Inc, Intelligent Automation, Inc., and Janssen Pharmaceuticals outside the submitted work. Dr Lockhart discloses receiving salary as Deputy Editor of Journal of Ultrasound in Medicine; Royalties, Elsevier Publishers; Royalties, Oxford Publishers. Dr Lyshchik reports personal fees and research support from General Electric, grants and non-financial support from Bracco Diagnostics, book royalties from Elsevier, Board of Governors and Deputy Editor of JUM from AIUM, outside the submitted work. Dr Purysko reports core radiology services from Profound medical, outside the submitted work. Dr Smith reports grants from General Electric, other from eMASS LLC, other from Radiostics LLC, outside the submitted work; In addition, Dr Smith has a patent Artificial intelligence-assisted tumor response with royalties paid, and a patent Target lesion tracking issued. The other authors state that they have no conflict of interest related to the material discussed in this article.

Keywords

  • AUC
  • Appropriate Use Criteria
  • Appropriateness Criteria
  • CT
  • Diagnostic imaging
  • MRI
  • Renal cell carcinoma
  • Surveillance
  • Ultrasound
  • X-ray

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Cancer'. Together they form a unique fingerprint.

Cite this